StageZero Life Sciences Ltd. — Regulatory Filings 2021

Apr 2, 2021

Note: {OJ Mar 2017] -Thefo/lowing is a consolidation of 13-501Fl. It incorporates amendments to this document that came into effect on March 1, 2017. This consolidation isprovided for your convenience and should not be relied on as authoritative.

FORM 13-501Fl CLASS I REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS - PARTICIPATION FEE

MANAGEMENT CERTIFICATION

==> picture [486 x 512] intentionally omitted <==

----- Start of picture text -----

I, , an officer of the reporting issuer noted below have examined this
Form 13-501Fl (the Form) being submitted hereunder to the Alberta Securities Commission and
certify that to my knowledge, having exercised reasonable diligence, the information provided in
the Form is complete and accurate.
April 1,2021
Name: James Howard-Tripp Date:
Title: Chairman and Chief Executive Officer
StageZero Life Sciences Ltd.
Reporting Issuer Name:
December 31,2020
End date of previous financial year:
Type of Reporting Issuer: [ x ] Class 1 reporting ] Class 3B reporting
issuer issuer
TOTONTO STOCK EXCHANGE
Highest Trading Marketplace:
Market value of listed or quoted equity securities:
SZLS
Equity Symbol
01/01/2020 31/03/2020
1st Specified Trading Period (dd/mm/yy) -to
Closing price of the security in the class or series on the
last trading day of the specified trading period in which
such security was listed or quoted on the highest trading
marketplace
----- End of picture text -----

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period (ii) Market value of class or series (i) x (ii) $ (A) 01/04/2020 2nd Specified Trading Period(dd/nun/yy) to Closing price of the security in the class or series on the last trading day of the specified trading periodinwhich such security was listed or quoted on the highest trading $ marketplace (iii) Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period (iv) (iii) x (iv) $ Market value of class or series (B) 3rd Specified Trading Period(dd/nun/yy) 01/07/2020 to Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period (vi) Market value of class or series (v) x (vi) $ (C)		38,184,335
		12,218,987.16 30/06/2020
		0.48 48,940,132 23,491,263.36 30/09/2020
		50,213,306 41,174,910.72

01/10/2020 31/12/2020

4th Specified Trading Period (dd/mm/yy)

==> picture [195 x 14] intentionally omitted <==

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace

==> picture [145 x 34] intentionally omitted <==

Number of securities in the class or series of such 60,716,595 security outstanding at the end of the last trading day of the specified trading period (viii) 45,537,446.06 (vii) x (viii) $ Market value of class or series (D)

5th Specified Trading Period (dd/mm/yy)

==> picture [195 x 24] intentionally omitted <==

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace

==> picture [145 x 27] intentionally omitted <==

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period (x) (ix) x (x) Market value of class or series Average Market Value of Class or Series (Calculate the simple average of the market value of the class or 30,605,651.83 series of security for each applicable specified trading $ period (i.e. A through E above)) (1)

(Repeat the above calculation for each other class or series of equity securities of the reporting issuer (and a subsidiary, if applicable) that was listed or quoted on a marketplace at the end of the previous financial year)

Fair value of outstanding debt securities:

(Provide details of how value was determined)

==> picture [145 x 35] intentionally omitted <==

30,605,651.83 Capitalization for tbe previous financial year (1) + (2) $ _ 2,590 Participation Fee $ _ Late Fee, if applicable 2,590 - Total Fee Payable $ (Participation Fee plus Late Fee)